摘要
目的观察达格列净辅助治疗血糖不达标2型糖尿病的效果。方法选取2021年1—6月东莞市水乡中心医院收治的血糖不达标2型糖尿病患者50例,根据随机数字表法分为试验组和对照组,每组25例。试验组应用达格列净辅助胰岛素强化治疗,对照组应用胰岛素强化治疗,2组均治疗3个月。比较2组治疗前后血糖指标[空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA_(1c))]、体质指数(BMI)、胰岛素用量、血清炎性因子[白介素-6(IL-6)、白介素-10(IL-10)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]及低血糖发生率。结果治疗3个月后,2组患者FBG、2 hPG及HbA 1c水平均低于治疗前,且试验组低于对照组(P<0.01);试验组患者BMI及胰岛素用量均低于治疗前及对照组(P<0.01),而对照组治疗3个月后无显著变化(P>0.05);2组患者IL-6、IL-10、CRP及TNF-α水平均低于治疗前,且试验组低于对照组(P<0.01);试验组发生低血糖2例(8.00%),对照组发生低血糖3例(12.00%),2组比较差异无统计学意义(χ^(2)=0.222,P=0.637)。结论达格列净辅助胰岛素强化治疗血糖不达标2型糖尿病可有效降低患者血糖水平、体质量及胰岛素使用量,缓解炎性反应,且低血糖发生率低。
Objective To observe the effect of dapagliflozin in adjuvant treatment of type 2 diabetes mellitus with substandard blood glucose.Methods Fifty patients of type 2 diabetes mellitus with substandard blood glucose admitted to Dongguan Waterfront Zone Central Hospital from January to June 2021 were selected,and they were divided into the test group and the control group according to the random number table,with 25 cases in each group.The test group was treated with dapagliflozin assisted insulin intensification,the control group was treated with insulin intensification,both groups were treated for 3 months.The blood glucose indexes[fasting blood glucose(FBG),2 hours postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA_(1c))],body mass index(BMI),insulin dosage,serum inflammatory factors[interleukin-6(IL-6),interleukin-10(IL-10),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]and the incidence of hypoglycemia were compared between the two groups before and after treatment.Results After 3 months of treatment,the levels of FBG,2 hPG and HbA 1c in the two groups were lower than those before treatment,and the test group was lower than the control group(P<0.01);The BMI and insulin consumption of patients in the test group were lower than those before treatment and the control group(P<0.01),but there was no significant change in the control group after 3 months of treatment(P>0.05);The levels of IL-6,IL-10,CRP and TNF-αin two groups were lower than before treatment,and the test group was lower than the control group(P<0.01);Hypoglycemia occurred in 2 cases(8.00%)in the test group and 3 cases(12.00%)in the control group,there was no statistically significant difference between the two groups(χ^(2)=0.222,P=0.637).Conclusion Dapagliflozin combined with intensive insulin treatment of type 2 diabetes mellitus with substandard blood glucose can effectively reduce the blood sugar level,boby mass and insulin dosage,alleviate inflammatory reactions,and low incidence of hypoglycemia.
作者
祝日华
游怡
陈泽康
ZHU Rihua;YOU Yi;CHEN Zekang(Department of internal medicine,Dongguan Waterfront Zone Central Hospital,Guangdong Province,Dongguan 523000,China)
出处
《临床合理用药杂志》
2023年第20期11-14,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
2型糖尿病
血糖不达标
达格列净
胰岛素用量
低血糖
Type 2 diabetes mellitus
Substandard blood glucose
Dapagliflozin
Insulin dosage
hypoglycemia
